Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 22, 2026.

Antitumor Compounds from Marine Actinomycetes

Carlos Olano, Carmen Méndez, José A. Salas

Marine Drugs · 2009 · Review · CC BY

doi:10.3390/md7020210

Abstract

Chemotherapy is one of the main treatments used to combat cancer. A great number of antitumor compounds are natural products or their derivatives, mainly produced by microorganisms. In particular, actinomycetes are the producers of a large number of natural products with different biological activities, including antitumor properties. These antitumor compounds belong to several structural classes such as anthracyclines, enediynes, indolocarbazoles, isoprenoides, macrolides, non-ribosomal peptides and others, and they exert antitumor activity by inducing apoptosis through DNA cleavage mediated by topoisomerase I or II inhibition, mitochondria permeabilization, inhibition of key enzymes involved in signal transduction like proteases, or cellular metabolism and in some cases by inhibiting tumor-induced angiogenesis. Marine organisms have attracted special attention in the last years for their ability to produce interesting pharmacological lead compounds.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Actinomycetes, characterized by a complex life cycle, are filamentous Gram-positive bacteria belonging to the phylum Actinobateria that represents one of the largest taxonomic units among the 18 major lineages currently recognized within the domain Bacteria. Actinobacteria are widely distributed in terrestrial and aquatic ecosystems, especially in soil, where they play a crucial role in the recycling of refractory biomaterials by decomposing complex mixtures of polymers in dead plant, animal and fungal materials. They are important in soil biodegradation and humus formation by the recycling of nutrients associated with recalcitrant polymers such as keratin, lignocelluloses and chitin and produce several volatile substances like geosmin responsible of the characteristic “wet earth odor”. They also exhibit diverse physiological and metabolic properties, such as the production of extracellular enzymes.

Around 23,000 bioactive secondary metabolites produced by microorganisms have been reported and over 10,000 of these compounds are produced by actinomycetes, representing 45% of all bioactive microbial metabolites discovered. Among actinomycetes, around 7,600 compounds are produced by Streptomyces species. Many of these secondary metabolites are potent antibiotics, which has made streptomycetes the primary antibiotic-producing organisms exploited by the pharmaceutical industry. Members of this group are producers, in addition, of clinically useful antitumor drugs such as anthracyclines (aclarubicin, daunomycin and doxorubicin), peptides (bleomycin and actinomycin D), aureolic acids (mithramycin), enediynes (neocarzinostatin), antimetabolites (pentostatin), carzinophilin, mitomycins and others. However, the search for novel drugs is still a priority goal for cancer therapy, due to the rapid development of resistance to multiple chemotherapeutic drugs. In addition, the high toxicity usually associated with cancer chemotherapy drugs and their undesirable side effects increase the demand for novel antitumor drugs active against untreatable tumors, with fewer side effects and/or with greater therapeutic efficiency.

Progress has been made recently on drug discovery from actinomycetes by using high-throughput screening and fermentation, mining genomes for cryptic pathways, and combinatorial biosynthesis to generate new secondary metabolites related to existing pharmacophores. In addition, in the last years the isolation of marine actinomycetes has been a great source of new compounds and their isolation all around the globe, from shallow costal sediments to the deepest sediments from the Mariana Trench, demonstrates that actinomycetes are ubiquitous in marine sediments, but at lower numbers than in soil. The oceans are highly complex environments and house a diverse assemblage of microbes that occur in environments with extreme variations in pressure, salinity, and temperature. The oceans cover around 70% of the Earth’s surface and present themselves as an unexplored area of opportunity. Marine microorganisms encompass a complex and diverse assemblage of microscopic life forms, of which it is estimated that only 1% has been cultured or identified. In addition, marine actinomycetes have been found in symbiosis with different marine invertebrates, especially sponges. Marine actinomycetes have attracted great attention since they have developed unique metabolic and physiological capabilities that not only ensure survival in extreme habitats, but also offer the potential to produce compounds with antitumor and other interesting pharmacological activities that would not be observed in terrestrial microorganisms, perhaps because of their close relationships with marine eukaryotic organisms including mammals. However, one of the main problems associated with marine actinomycetes is the difficulty often found for their culture, due to specific requirements like sea salt, since in some cases these microorganisms are obligate halophiles. There are a number of reports on techniques and approaches for accessing previously uncultured soil actinomycetes and the biosynthesis gene clusters they harbor. In the case of marine actinomycetes these studies are only beginning, but there have already been several attempts to optimize their isolation and growth from several sources as well as the improvement of the fermentation process for the production of specific compounds and the development of tools to facilitate the genetic manipulation of the isolated biosynthesis gene clusters.

In this review we focus on novel antitumor compounds identified from marine actinomycetes and classified them in terms of their chemical structure (Table 1), covering the literature until February 2009.

2. Polyketides

Polyketides are a large family of natural products produced by step-wise decarboxylative Claisen-type condensation of acyl-CoA precursors, reactions catalyzed by polyketide synthases (PKSs). The carbon skeleton of polyketides may be further reduced and modified based on the programming encoded by different domains present in PKSs with ketoreductase, dehydratase and enoylreductase activities. Three types of PKSs are known to date: type I PKSs are multifunctional enzymes organized into modules, type II PKSs are multienzyme complexes carrying out a single set of activities and type III PKSs, also known as chalcone synthase-like PKSs, are iteratively acting condensing enzymes.

A high number of type I polyketide derived compounds with antitumor activity have been isolated from marine actinomycetes. Such is the case of arenicolides (Figure 1), 26-membered polyunsaturated macrolactones, produced by the obligate marine actinomycete Salinispora arenicola strain CNR-005 isolated from a marine sediment sample collected at a depth of 20 m from the coastal water around the island of Guam.

In particular, arenicolide A was found to exhibit moderate cytotoxicity toward the human colon adenocarcinoma cell line HCT-116 with an IC50 of 30 μg/mL. Two bicyclic polyketides, saliniketal A and B (Figure 1), were also isolated from the same strain of S. arenicola. Using cultures of human bladder carcinoma T24 cells in conjunction with terephthalic acid, a potent tumor promoter that induces ornithine decarboxylase (ODC), saliniketals were found to inhibit ODC induction with IC50 values of 1.95 and 7.83 μg/mL, respectively. ODC, an important target for the chemoprevention of cancer, is a directed transcriptional target of the oncogene myc and is overexpressed in various tumor cells.

Several macrolactones have been reported in addition to the arenicolides (Figure 1). IB-96212, a 26-membered macrolide that contains a spiroketal lactone structure, is produced by Micromonospora sp. L-25-ES25-008 isolated from a sponge collected at the Indian Ocean near the coast of Mozambique. This compound showed cytotoxic activity against mouse leukemia P-388 and human lung non-small cell A-549, colon adenocarcinoma HT-29 and melanoma MEL-28 cell lines. The activity against P-388 cell line was four orders of magnitude higher than the activity against A-549, HT-29 and MEL-28 cell lines. Chalcomycin, a 16-membered macrolide, is produced by Streptomyces sp. M491 isolated from the Qingdao coast (China). In addition, chalcomycin and the related compound chalcomycin B have been isolated from Streptomyces strain B7064 found in mangrove sediments in Hawaii. Chalcomycin has been found to inhibit protein synthesis in HeLa human cervix carcinoma cell line. The biosynthesis gene cluster of this compound was isolated and characterized from S. bikiniensis. Aureoverticillactam is a 22-membered macrocyclic lactam produced by S. aureo-verticillatus NPS001583 isolated from marine sediments. Aureoverticillactam was found to possess moderate growth inhibitory activity against human colorectal adenocarcnioma HT-29, Jurkat leukemia and mouse melanoma B16F10 cell lines.

To a novel class of polyketides belong marinomycins (Figure 2), unusual macrodiolides composed of dimeric 2-hydroxy-6-alkenyl-benzoic acid lactones with conjugated tetraene-pentahydroxy polyketide chains, produced by Marinispora sp. CNQ-140 isolated from a sediment sample collected at a depth of 56 m offshore of La Jolla, California. These compounds inhibit cancer cell proliferation with an average LC50 of 0.2–2.7 μM against the NCI’s 60 cancer cell line panel. Marinomycin A showed significant tissue type selectivity being more active against human melanoma cell lines LOX IMVI, M14, SK-MEL-2, SK-MEL-5, UACC-257, and UACC-62. The most sensitive strain was melanoma SK-MEL-5 with an LC50 of 5.0 nM. Marinomycins B and C also showed potent activities with average LC50 values of 0.9 and 0.2 μM, respectively. The potent and selective antitumor activity of these compounds suggests a specific, but as yet unknown, mechanism of action.

The manumycins (Figure 3) constitute a class of compounds with antibiotic, cytotoxic, and other biological activities. It has been reported that manumycin A and its analogues inhibit Ras farnesyl transferase and the growth of Ki-ras-activated murine fibrosarcoma in mice. The side chains in manumycins appear to be a typical polyketide-derived moiety, differing with respect to their combinations of starter and elongation units. The central cyclohexene ring may be derived from the polyketide as in the case of manumycins or from some modified amino acid like 3-amino-5-hydroxybenzoic acid. Manumycin A and chinikomycins A and B (the quinone form of chinikomycin A) were isolated from Streptomyces sp. M045 derived from sediment of Jiaozhou Bay in China. Chinikomycins A and B showed moderate antitumor activity. Chinicomycin A selectively inhibited proliferation in cell lines of mammary cancer MAXF 401NL (IC50 of 2.41 μg/mL), melanoma MEXF 462NL (IC50 of 4.15 μg/mL), and renal cancer RXF 944L (IC50 of 4.02 μg/mL). Chinikomycin B showed selective antitumor activity against the mammary cancer cell line MAXF 401NL (IC50 of 3.04 μg/mL). Daryamides belong also to the manumycin family of compounds. They were isolated from Streptomyces strain CNQ-085 obtained from marine sediment collected at a depth of 50 m off San Diego coast, California. Daryamides A to C and (2E,4E)-7-methylocta-2,4-dienoic acid amide were subjected to cytotoxicity evaluation against the human colon carcinoma cell line HCT-116 showing that daryamide A exhibited significantly more potent cancer cell cytotoxicity, with an IC50 of 3.15 μg/mL, than daryamides B and C.

Even though it is not produced by a marine actinomycete we include in this review the antitumor compound lissoclinolide (Figure 3) isolated from the marine ascidian Lissoclinum patella. This compound was originally isolated from a fungus and a soil actinomycete, which points to an actinomycete associated to L. patella as the true source of lissoclinolide. This compound, a small non-nitrogenous lactone with a putative polyketide origin probably synthesized by a type I PKS, was able to inhibit cell growth in various mammalian tumor lines at an average IC50 of 395 nM, and in particular the human colon tumor COLO 205, HCC-2998, HCT-116 and HCT-15 cell lines which resulted in a strong arrest in the G2/M phase of the cell cycle.

Four new polyketides (Figure 4), salinipyrones (A and B), and pacificanones (A and B) have been isolated from cultures of the obligate marine actinomycete Salinispora pacifica CNS-237 found in a sediment sample collected in the Palau island, western Pacific Ocean. The biological activity of these compounds is currently being examined in diverse bioassays. In initial screening, the salinipyrones and the pacificanones displayed no significant activity in a cancer cytotoxicity assay using HCT-116 human colon cancer cells. In an isolated mouse splenocyte model of allergic inflammation, salinipyrone A displayed moderate inhibition of interleukin-5 production by 50% at 10 μg/mL without measurable human cell cytotoxicity. The same apparent lack of biological activity has been found also for the polyketides sporolide A and B (Figure 4) produced by Salinispora tropica strain CNB-392 isolated from marine sediments near Chub Cay (Bahamas) and actinofuranones A and B (Figure 4) isolated from culture extract of Streptomyces strain CNQ766 derived from a sediment sample collected from Guam. Sporolides displayed no activity against human colon carcinoma HCT-116 cells and showed no significant antibiotic activity. Actinofuranones showed weak in vitro cytotoxicity against mouse splenocyte T-cells and macrophages with IC50 values of 20 μg/mL and were inactive against human colon carcinoma HCT-116 cells. Cyanosporasides A and B (Figure 4) are cyclopenta[a]indene glycosides structurally related to sporolides and proposed to be cyclization products of an enediyne precursor probably synthesized by an iterative type I PKS. They have been isolated from the culture broth of S. pacifica strain CNS103 isolated from sediments collected at a depth of 500 m in Palau island. To date, limited testing has shown that cyanosporaside A has weak cytotoxicity against human colon carcinoma HCT-116 (IC50 30 μg/mL).

Piericidins C7 and C8 (Figure 4), probably synthesized by type I PKS, are produced by Streptomyces sp. YM14–060 isolated from an unidentified ascidian collected at Iwayama Bay, Palau Island. The biological activity of piericidins was examined using rat glial cells transformed with the adenovirus E1A gene (RG-E1A-7), Neuro-2a mouse neuroblastoma cells, C6 rat glioma cells and 3Y1 rat normal fibroblast. The adenovirus E1A gene product inactivates the retinoblastoma tumor suppressor protein that plays an important role in cell-cycle and apoptosis control in mammalian cells and is inactivated during the development of a wide variety of cancers. Piericidins C7 and C8 showed selective cytotoxicity against RG-E1A-7 cells (IC50 of 1.5 nM and 0.45 nM, respectively) and inhibited the growth of Neuro-2a cells (IC50 of 0.83 nM and 0.21 nM, respectively) without cytotoxic cell death. On the other hand, C6 rat glioma cells and 3Y1 rat normal fibroblast were not affected by piericidins.

Nonactin (Figure 4), a cyclic polyether also known as macrotetrolide, has been isolated from cultures of Streptomyces sp. KORDI-3238 isolated from a deep-sea sediment sample collected at Ayu Trough in the western Pacific Ocean. The biosynthesis gene cluster of nonactin has previously been isolated and characterized from S. griseus DSM40695 revealing that it is synthesized by a non-iteratively acting type II PKS that involves five ketosynthases and lacks the acyl carrier protein. Nonactin has been shown to be an effective inhibitor against the multidrug-resistant human erythroleukemia cell line K-562.

Aromatic polyketides are synthesized by type II PKS and are further divided into different structural classes such as anthracyclines, angucyclines and tetracyclines among others. To the anthracycline family of compounds belongs komodoquinone A, and its aglycone, komodoquinone B (Figure 5) produced by Streptomyces sp. KS3 isolated from marine sediments. Komodoquinone A is a unique anthracycline, in which a previously unknown amino sugar is attached to C4 instead to C7 as in the most known anthracyclines. Komodoquinone A was found to induce neuronal cell differentiation in the neuroblastoma cell line Neuro-2a at a concentration of 1 μg/mL, an activity not shown by doxorubicin. Treatment with komodoquinone A arrested Neuro-2a cells at the G1 phase while these treated with adriamycin were arrested at the G2/M phase. These data suggested that the amino sugar moiety attached to C4 might be important for neuritogenic activity of komodoquinone A, activity probably exerted by a mechanism different from the intercalation in DNA. Another anthracycline related compound, chartreusin, has been isolated from cultures of Streptomyces sp. QD518 isolated from the Jiaozhou Bay of Quindao, China. Chartreusin (Figure 5) is an aromatic glycosylated polyketide, currently in phase II clinical trials, that possesses an unusual bislactone synthesized through anthracycline intermediates that might undergo a series of oxidative rearrangements to generate the final bislactone structure. This particular biosynthetic process has been unraveled by the isolation of the chartreusin biosynthesis gene cluster from S. chartreusis. Chartreusin has been shown to exert antitumor activity through binding to DNA, radical-mediated single-strand breaks and inhibition of topoisomerase II. It possesses a significant chemotherapeutic activity against various tumor cell lines such as murine P388 and L1210 leukemia, and B16 melanoma cells. Streptomyces sp. B6921 is the producer of several anthracycline C-glycosides such as fridamycin D, himalomycin A and B, and the angucycline rabelomycin (Figure 5). Only antibiotic activity has been reported for these compounds. However, other compounds analogous to fridamycin D and himalomycin A and B such as vineomycins have been shown to exhibit antitumor activity against Sarcoma-180 solid tumor in mice.

Several compounds of the anthraquinone family (Figure 6), closely related to anthracyclines, are produced by Streptomyces sp. isolate B8652 derived from a sediment of the Laguna de Términos at the Gulf of México. All these compounds, parimycin, trioxacarcins and gutingimycin, showed antitumor activities at different degrees. It has been shown that trioxacarcin A forms a stable complex with dsDNA and the cleavage of these complexes provided the natural product gutingimycin by guanine abstraction. Parimycin showed activity against human tumor cell lines of stomach cancer GXF 251L, lung cancer H460, LXFA 629L, and LXFL 529L, breast cancer MCF-7 and MAXF 401NL, melanomas MEXF 462NL and MEXF 514L with IC70 values ranging from 0.9 to 6.7 μg/mL. Trioxacarcins A to D showed pronounced antitumor activities with mean IC70 values ranging from 0.001 to 2.161 μg/mL against human tumor cell lines of colon cancer HT-29, melanoma MEXF 514L, lung adenocarcinoma LXFA 526L, large cell lung cancer LXFL 529L and H-460, central nervous system SF-268, mammary cancer MCF-7, prostate cancer PC3M, and renal cancer RXF 631L. Trioxacarcin A was the most potent of all trioxacarcins, and gutingimycin was the less active with a mean IC70 value of 3.386 μg/mL. Trioxacarcin A also proved to be very toxic in preliminary in vivo experiments in tumor bearing nude mice, being the maximum tolerated dose between 0.1 and 0.3 mg/kg. Trioxacarcins B to D showed selective antitumor activity against certain tumor cell lines. Another compound from the same family, 1,8-dihydroxy-2-ethyl-3-methylanthraquinone, has been identified from cultures of Streptomyces sp. FX-58, which was isolated from marine plant Salicornia herbacea collected in Qingdao, Shandong province, China. This compound showed inhibitory effect against human tumor cell lines of pro-myelocytic leukemia HL-60, gastric carcinoma BGC-823 and adenocarcinoma MDA-MB-435 with IC50 of 6.83, 82.2 and 56.59 μg/mL, respectively.

Tetracenomycin D and other quinone-related compounds with antitumor activity have been isolated from different marine acinomycetes (Figure 6). S. chinaensis AUBN1/7 isolated from marine sediment samples of Bay of Bengal, India, is the producer of 1-hydroxy-1-norresistomycin and resistoflavin. These compounds together with resistomycin and tetracenomycin D are produced by Streptomyces sp. B8005 isolated from sediments of the Laguna de Términos at the Gulf of México. Resistomycin was isolated, in addition, from Streptomyces sp. B4842 from mud sediment of a coastal site of Mauritius, Indian Ocean. Tetracenomycin D was previously showed to possess cytotoxic activity and it has been isolated from S. glauscescens as an intermediate in the biosynthesis of tetracenomycin D, whose biosynthesis gene cluster has been studied and used for the generation of several derived compounds. Resistomycin, among other activities, has also been proposed to be a modulator of apoptosis. The biosynthesis gene cluster of resistomycin has been isolated and characterized from S. resistomycificus, and, as expected, involves a type II PKS. 1-hydroxy-1-norresistomycin and resistoflavin showed cytotoxic activity against human gastric adenocarcinoma HMO2 and hepatic carcinoma HePG2 cell lines.

Two new cytotoxic quinones of the angucycline class, marmycins A and B (Figure 7) were isolated from the culture broth of Streptomyces strain CNH990 isolated from a sediment sample collected at a depth of 20 m at the entrance to the Sea of Cortez, 5 km east of Cabo San Lucas, México. In cytotoxic assays using the human cell line of colon adenocarcinoma HCT-116, marmycin A showed an IC50 of 60.5 nM, almost 18 times more potent than marmycin B, which showed an IC50 of 1.09 μM. Marmycin A was further evaluated for its in vitro cytotoxicity showing a mean IC50 value of 0.022 μM against 12 human tumor cell lines (breast, prostate, colon, lung, leukemia). In the same assays marmycin B was significantly less potent with a mean IC50 value of 3.5 μM. SS-228 Y (Figure 7) is an angucycline type compound produced from a species of Chainia (now Streptomyces) isolated from shallow sea mud in Sagami Bay. During SS-228 Y structural characterization this compound was found to be very labile to light and heat, being converted into the anthracycline like compound SS-228 R. SS-228 Y inhibits growth of Ehrlich breast adenocarcinoma in mice. A prolongation of the survival period was observed in mice inoculated with Ehrlich ascites tumor when SS-228 Y was administered for 10 days at doses of more than 1.56 μg per day. The acute toxicity of SS-228 Y, shown by LD50, in mice was between 1.56 and 6.25 mg/kg by intraperitoneal injection.

IB-00208 (Figure 7) is a polycyclic xanthone related to angucyclines and other aromatic polyketides. It was isolated from Actinomadura sp BL-42-PO13-046 collected in the northern coast of Spain associated to a polychaete. IB-00208 showed a potent cytotoxic activity against mouse leukemia P-388 and human lung non-small cell A-549, colon adenocarcinoma HT-29 and melanoma SK-MEL-28 cell lines. Griseorhodin A (Figure 7), that belongs to the family of pentangular polyphenols related to angucyclines and other aromatic polyketides, is an inhibitor of human telomerase, a ribonucleoprotein complex involved in the stabilization of telomere length in stem cells and reproductive cells and found in almost all human tumors but not in adjacent normal cells. The biosynthesis gene cluster for griseorhodin A has been isolated and characterized from Streptomyces sp. JP95 associated with the marine ascidian Aplidium lenticulum collected at Heron Island, Queensland, Australia.

3. Non-Ribosomal Peptides

This class of natural products comprises peptides synthesized by non-ribosomal peptide synthetases (NRPS). The amino acid monomers incorporated by NRPS assembly lines are aminoacyl-AMP mixed anhydrides that follow the same chemical logic as PKSs for chain elongation and are then modified based on the program encoded by different domains present in NRPS modules, which can include epimerization, methyltransferase, reductase or oxidase activities. Quite often non-ribosomal peptides also contain some unique structural features such as heterocyclic elements and deoxysugars.

Proximicins (Figure 8) are aminofuran antibiotics, probably synthesized by a NRPS system, produced by Verrucosispora strain MG-37 and V. maris AB-18–032, and isolated from sediments collected at a depth of 250 m in the Raune Fjord, Norway and the Sea of Japan at a depth of 289 m, respectively. Proximicins A, B and C showed significant growth inhibitory activities towards human gastric adenocarcinoma AGS (GI50 of 0.6, 1.5 and 0.25 μM, respectively) and hepatocellular carcinoma Hep G2 (GI50 of 0.82, 9.5 and 0.78 μM, respectively), and were found to induce arrest AGS cells in G0/G1 and to increase the levels of p53 and p21. Lucentamycins (Figure 8), 3-methyl-4-ethylideneproline-containing peptides, are produced by Nocardiopsis lucentensis strain CNR-712 isolated from sediment collected from a shallow saline pond on the island of Little San Salvador, in the Bahamas. Lucentamycins A and B showed significant in vitro cytotoxicity against human colon carcinoma HCT-116 cell line with IC50 values of 0.20 and 11 μM, respectively. However, lucentamycins C and D were not cytotoxic in the same assay suggesting that the presence of an aromatic ring is essential for the biological activity of this class of compounds. Mechercharmycins (Figure 8) are produced by Thermoactinomyces sp. YM3-251, isolated from sea mud collected at Mecherchar in the Republic of Palau (North Pacific Ocean). While mechercharmycin A showed cytotoxic activity against human lung adenocarcinoma A549 and Jurkat leukemia cells with IC50 values of 0.04 μM, mechercharmycin B did not show inhibitory activity in these assays even at 1 μM, which suggests the cyclic structure of mechercharmycin A must be essential for the antitumor activity.

Thiocoraline (Figure 9) is a 2-fold symmetric bicyclic non-ribosomally synthesized octathiodepsipeptide, characterized by the presence of peptide and ester bonds, produced by Micromonospora sp. L-13-ACM2-092 isolated from a soft coral collected at the Indian Ocean near the coast of Mozambique. It shows potent antitumor activity against murine leukemia P388, human lung adenocarcinoma A549, and melanoma MEL288, being the activity against these cell lines 5-fold more potent than for human colon adenocarcinoma HT-29 cell line (IC50 values of 0.002 vs. 0.01 μM, respectively). In addition, on both LOVO and SW620 human colon cancer cell lines, thiocoraline caused an arrest in G1 phase of the cell cycle and a decrease in the rate of S phase progression towards G2/M phases, due to its DNA bisintercalative properties and its DNA polymerase α inhibition. Thiocoraline is structuraly related to other bisintercalator compounds of the quinoxaline family with potential therapeutic applications like echinomycin, inhibitor of hypoxia-inducible factor-1 that controls genes important for tumor progression and metastasis that are involved in glycolysis, angiogenesis, migration, and invasion. The biosynthesis gene cluster of thiocoraline has been isolated, characterized and heterologously expressed in S. lividans and S. albus.

Three new cyclohexadepsipeptides, arenamides (Figure 9), were isolated from the fermentation broth of a marine bacterial strain identified as S. arenicola CNT-088 which was obtained from a marine sediment sample collected at a depth of 20 m off the Great Astrolab Reef, in the Kandavu Island chain, Fiji. Arenamides A and B exhibited weak in vitro cytotoxicity against human colon carcinoma HCT-116 with IC50 values of 13.2 and 19.2 μg/mL, respectively.

In addition, arenamides have been associated to chemoprevention of carcinogenesis by suppression of NFκB activation. NFκB regulates the expression of a number of genes, the products of which are involved in tumorigenesis. The effect of arenamides on NFκB activity was studied with stably transfected 293/NFκB-Luc human embryonic kidney cells induced by treatment with tumor necrosis factor (TNF). Arenamides A and B blocked TNF-induced activation in a dose- and time-dependent manner with IC50 values of 3.7 and 1.7 μM, respectively. Piperazimycins (Figure 9) are cyclic hexadepsipeptides isolated from the fermentation broth of a Streptomyces sp. strain CNQ-593, cultivated from marine sediments samples collected at a depth of approximately 20 m near the island of Guam. Antitumor activities for piperazimycins were initially evaluated in vitro against the human colon carcinoma HCT-116 cell line. All compounds exhibited significant cytotoxicity with an average GI50 of 76 ng/mL for each. Piperazimycin A also showed potent biological activity when evaluated against the NCI’s cancer cell line panel, with mean GI50, TGI and LC50 values for all cell lines of 100 nM, 300 nM and 2 μM, respectively. Overall, piperazimycin A exhibited a nearly 3-fold more potent activity against solid tumors (average LC50 of 13.9 μM) than against the leukemia cell lines tested (average LC50 of 31.4 μM), being most active against the melanoma (average LC50 of 0.3 μM), central nervous system (average LC50 of 0.4 μM), and prostate cell lines (average LC50 of 0.6 μM) cancers.

4. Mixed Polyketide-Nonribosomal Peptides

As mentioned above, NRPSs and type I PKSs are multifunctional proteins that are organized into modules and use a similar strategy for the assembly of these two distinct classes of natural products. The combined use of NRPSs and type I PKSs allows assembling hybrid polyketide/non-ribosomal peptide compounds derived from amino acids and short-chain carboxylic acids.

The most known compound of this family is salinosporamide A (Figure 10), a highly potent inhibitor of the 20S proteasome currently in phase I clinical trials for the treatment of cancer. It is produced by S. tropica strain CNB-392 isolated from a sediment sample collected at a depth of about 1 m from a mangrove environment in Chub Cay, Bahamas and other S. tropica strains like CNB-440 and CNB-476 isolated also from Bahamas. Salinosporamide A displayed potent in vitro cytotoxicity against human colon carcinoma HCT-116 with an IC50 value of 11 ng/mL, and was shown potent and highly selective in the NCI’s 60 cell line panel. The greatest potency was observed against human cell lines of non-small cell lung cancer NCI-H226, central nervous system cancer SF-539, melanoma SK-MEL-28, and breast cancer MDA-MB-435 (all with LC50 values less than 10 nM). When salinosporamide A was tested against purified rabbit muscle 20S proteasome, a multicatalytic complex responsible for degrading most intracellular proteins in eukaryotes, it inhibited proteasomal chymotrypsin-like proteolytic activity with an IC50 value of 1.3 nM. The 26S proteasome, composed of 19S and 20S components, is a multicatalytic complex responsible for degrading most intracellular proteins in eukaryotes. Three distinguishable proteolytic activities are localized in the 20S proteasome and are classified as chymotrypsin-, caspase-, and trypsin-like, all of them inhibited by salinosporamide A, in particular chymotrypsin and caspase-like. Compounds of the same family, salinosporamides B-J (Figure 10), have been isolated together with salinosporamide A from S. tropica. In addition, new derivatives of salinosporamide A were produced by replacement of synthetic sea salt with sodium bromide in the fermentation media of S. tropica that led to the production of bromosalinosporamide, and by derivatization of salinosporamide A and B leading to the production of several thioester analogues (designed as T in Figure 10). Salinosporamide A thioester derivatives T1 and T2 were found potent 20S proteasome inhibitors with IC50 values of 3.6-and 1.5-fold higher than salinosporamide A. The characterization of the salinosporamide A biosynthesis gene cluster during the sequencing of S. tropica CNB-440 circular genome has allowed the generation of several derivatives such as fluorosalinosporamide produced by mutasynthesis using a chlorinase salL mutant, and antiprotealide (Figure 10) produced by a combination of genetic engineering and precursor-directed biosynthesis. Antiprotealide has been recently found as a natural product produced by different strains of S. tropica.

Lajollamycin (Figure 10) is another mixed polyketide/non-ribosomal peptide produced by S. nodosus strain NPS007994 isolated from marine sediments collected in Scripps Canyon, La Jolla, California. Lajollamycin was found to inhibit the growth of murine melanoma cell line B16-F10, with an EC50 of 9.6 μM. The biosynthesis gene cluster of oxazolomycin, a structural close relative of lajollamyin, has been isolated and characterized from S. albus JA3453 confirming the hybrid peptide-polyketide origin of these compounds.

5. Isoprenoids

Isoprenoids, similar to terpenes, are one of the largest families of natural compounds. Isoprenoids are derived from five-carbon isoprene units assembled and modified in different ways. They are classified into several groups based on the number of C5 units that form part of their structure: monoterpenes (C10), sesquiterpenes (C15) and diterpenes (C20).

Altemicidin (Figure 11) with a monoterpene-alkaloid skeleton is produced by S. sioyaensis SA-1758 isolated from sea mud collected at Gamo, Miyagi Prefecture, Japan. This compound was found to inhibit the growth of murine lymphoid leukemia L1210 and carcinoma IMC cell lines with IC50 values of 0.84 and 0.82 μg/mL, respectively, although it showed high acute toxicity in mice.

Marinones (Figure 11) are sesquiterpenoid naphthoquinones with a mixed polyketide-terpenoid origin. Neomarinone, isomarinone, hydroxydebromomarinone and methoxydebromomarinone were produced by actinomycete isolate CNH-099 obtained from a sediment sample taken at 1 m depth in Batiquitos Lagoon, North of San Diego, California. These compounds showed moderate in vitro cytotoxicity, IC50 of 8 μg/mL, against human colon carcinoma HCT-116 cells. In addition, neomarinone generated a mean IC50 value of 10 μM in the NCI’s 60 cancer cell line panel. T-muurolol sesquiterpernes (Figure 11) were isolated from Streptomyces strain M491 derived from sediment obtained from Jiaozhou Bay, Qingdao coast, China. Seven out of eight sesquiterpenes of the T-muurolol family were tested for their cytotoxycity against 37 human tumor cell lines but, except for 15-hydroxy-T-muurolol which was moderately cytotoxic with an IC50 of 6.7 μg/mL, the other compounds including 3-oxo-T-muurolol, 11,15-dihydroxy-T-muurolol, T-muurolol and 3α-hydroxy-T-muurolol showed no activity.

Several chlorinated dihydroquinones (1–5, Figure 12), with a mixed terpenoid/polyketide origin, are produced in saline culture of the actinomycete strain CNQ-525, isolated from ocean sediments collected at a depth of 152 m near La Jolla, California. Dihydroquinones 4 and 5 were identical to the previously reported antibiotics A80915A and A80915C produced by soil actinomycete S. aculeolatus. Dihydroquinones 1, 2 and 4 were found to be cytotoxic toward human colon carcinoma HCT-116 cells with IC50 of 2.4, 0.97 and 1.84 μg/mL, respectively.

Actinobacterium sp. MS1/7 isolated form sediments taken at the Bay of Bengal is the producer of compound 4a,8a-dimethyl-6-(2-methyl-propenyloxy)-3,4,4a,4b,5,6,8a,9-octahydro-1H-phenanthren-2-one (Figure 12), with putative isoprenoid origin. This compound was found to inhibit the growth by 54% of human leukemia HL-60 cell line at 0.05 μg/mL and to possess a reduced toxicity against non-tumor cells since only 2.3% of murine erythrocytes and 1.6% of human erythrocytes were lysed at concentrations of 35–40 μg/mL.

6. Indolocarbazoles

Most of the compounds of this family contain a characteristic indolo[2,3-a]pyrrolo[3,4-c]carbazole core derived from two units of tryptophan, with sugars attached derived from glucose and methionine. These compounds constitute a separate type of antitumor drugs with several mechanisms of action including DNA-damage targeting on topoisomerases I and II, and inhibition of protein kinases, including serine/threonine and tyrosine kinases. One of the better known indolocarbazole, staurosporine (Figure 13) has been isolated from several marine actinomycetes including komodoquinones-producer Streptomyces sp. KS3 after its discovery from cultures of S. staurosporeus AM-2282. The staurosporine biosynthesis gene cluster was identified and characterized from Streptomyces sp. TP-A0274 and S. longisporoflavus, which has led to the generation of several derivatives of indolocarbazoles staurosporine and rebeccamycin with antitumor activity. Staurosporine has been isolated, in addition, together with two natural analogues, 4′-N-methyl-5′-hydroxystaurosporine and 5′-hydroxystaurosporine (Figure 13) from Micromonospora sp. L-31-CLCO-002 obtained from a homogenate of the sponge Clathrina coriacea collected on the Coast of Fuerteventura Island in the Canary Islands archipelago.

The cytotoxic activities of these indolocarbazoles were determined in vitro in cell cultures of murine macrophague P388D1 (IC50 of 0.01, 0.02 and 0.04 μg/mL), human lung adenocarcinoma A549 (IC50 of 0.0005, 0.002 and 0.004 μg/mL), colon adenocarcinoma HT-29 (IC50 of 0.02, 0.004 and 0.004 μg/mL) and melanoma SK-MEL-28 cell lines (IC50 of 0.001, 0.002 and 0.004 μg/mL). Staurosporine showed the strongest activity against P388D1, A549 and SK-MEL-28 cell lines, while 4′-N-methyl-5′-hydroxystaurosporine and 5′-hydroxystaurosporine were more active against HT-29 cell line. N-formyl- and N-carboxamido-staurosporines have been isolated from cultures of Streptomyces sp. QD518 isolated from the Jiaozhou Bay of Quindao, China. N-formyl- and N-carboxamido-staurosporines were tested in vitro for antitumoral activity in a panel of 37 human tumor cell lines derived from solid human tumors. N-carboxamido-staurosporine was found to be the most potent compound with a mean IC50 and IC70 values of 0.016 and 0.17 μg/mL, respectively, while N-formyl-staurosporine showed also high activity with mean IC50 and IC70 values of 0.063 and 0.37 μg/mL, respectively. ZHD-0501 (Figure 13) is a novel naturally occurring staurosporine analog carrying a heterocycle fused to the pyran ring produced by Actinomadura sp. 007, strain isolated from a sea sediment sample collected in Jiaozhou Bay, China. ZHD-0501 was shown to inhibit the proliferation of human lung adenocarcinoma A549, hepatocarcinoma BEL-7402, and pro-myelocytic leukemia HL60 cancer cell lines and mouse leukemia P388 cells with the inhibition rates of 82.6%, 57.3%, 76.1%, and 62.2% at 1 μM, respectively. It also inhibited the proliferation of mouse mammary cancer tsFT210 cells, by inhibiting the cell cycle at the G2/M phase, with the inhibition rates of 28.3% at 21 μM and 20.5% at 2.1 μM.

Two known indolocarbazole alkaloids with anticancer properties, K252c (staurosporine aglycon) and arcyriaflavin A (Figure 13), are produced by marine actinomycete strain Z2039-2, isolated from the sea sediment collected on the coast of Qingdao, China. K252c was found to induce 57.3% apoptosis on culture of human chronic myelogenous leukemia K562 cell line at 10 μM and nearly 100% at 100 μM. In the same assay arcyriaflavin A induced 25.9% apoptosis at 10 μM and up to 68.93%, at 100 μM. K252c and arcyriaflavin A have been found, in addition, to reduced the relative resistance of cells transfected with ABCG2, a transporter with potential importance in cancer drug resistance, to SN-38 (7-ethyl-10-hydroxycamptothecin) in cytotoxicity assays. Several analogues of K252c and arcyriaflavin A have been generated using genes involved in rebeccamycin biosynthesis.

Lynamicins (Figure 13) bisindole pyrroles are related to bisindolylmaleimides and indolocarbazoles due to their close structural and biosynthetic relationships, are produced by Marinispora sp. NPS12745 isolated from a marine sediment collected off the coast of San Diego, California. These compounds have been only tested for antimicrobial activity showing good potency against staphylococci and enterococci. However, there are reports of bisindolylmaleimide derivatives with potent antitumor and antiangiogenic properties and with potential to reduce resistance mediated by transporter ABCG2.

7. Others

Marineosins (Figure 14), related to the prodigiosin class of polypyrrole bacterial pigments, are spiroaminal compounds containing two pyrrole functionalities produced by Streptomyces strain CNQ-617 isolated from a marine sediment sample collected off shore of La Jolla, California. Marineosins showed significant inhibition of human colon carcinoma HCT-116 cell line with IC50 values of 0.5 μM for marineosin A and 46 μM for marineosin B. These differences might be due to the configuration at the spiroaminal center. In addition, marineosin A showed selectivity against melanoma and leukemia cell lines in the NCI’s 60 cell line panel. Additionally, two known compounds of the prodigiosin family have been isolated from cultures of Saccharopolyspora sp. nov. actinomycete isolated from sponge Mycale plumose collected along the coast of Qingdao, China. The compounds identified as metacycloprodigiosin and undecylprodigiosin exhibited significant cytotoxic activities in vitro, as it has been recently described for prodigiosin family of compounds, against five cancer cell lines: mouse lymphoma P388, human peripheral blood promyeloblast HL60, lung carcinoma A-549 and SPCA4, and hepatic carcinoma BEL-7402 with IC50 values between 0.007 and 7.52 μM for metacycloprodigiosin and 0.013 to 0.11 μM for undecylprodigiosin.

Streptopyrrolidine (Figure 14) is a benzyl tetrahydropyrrole derivative produced by Streptomyces sp. KORDI-3973 isolated from a deep-sea sediment sample collected at Ayu Trough, in the southern Philippine Sea. Streptopyrrolididine showed anti-angiogenesis activity on human umbilical vein endothelial cells (HUVECs) based capillary tube formation assay. The inhibition of tube formation was exerted without showing cytotoxicity against HUVECs at the concentration of 100 μg/mL.

Ammosamides (Figure 14) are pyrroloiminoquinone compounds produced by Streptomyces strain CNR-698 isolated from bottom sediments collected at a depth of 1,618 m in the Bahamas Islands. Ammosamide A and B exhibited significant in vitro cytotoxicity against human colon adenocarcinoma HCT-116 cells with an IC50 of 320 nM each. These compounds were shown highly selective against a diversity of cancer cell lines with values ranging from 20 nM to 1 μM, indicating a specific target mechanism of action that was identified as a member of the myosin family, important cellular proteins that are involved in numerous cell processes, including cell cycle regulation, cytokinesis, and cell migration.

Bohemamines (Figure 14) are pyrrolizidine alkaloids produced by Streptomyces strain CNQ-583 cultured from a marine sediment sample collected at a depth of 82 m off the island of Guam. Bohemamine, bohemamine B, bohemamine C and 5-chlorobohemamine C were tested for inhibition of the human colon adenocarcinoma HCT-116 cell line but were found to be inactive. However, bohemamine and deoxybohemamine were shown to be inhibitors of cell adhesion based on LFA-1/ICAM-1 capable of inhibiting adhesion of human pro-myelocytic leukemia HL-60 cells to Chinese hamster ovary cells transfected with human ICAM-1, at IC50 values of 24.3 and 27.2 μg/mL, respectively. The interaction between LFA-1, also frequently expressed on hematopoietic and solid cancer cell types, and ICAM-1, that in its circulating form promotes angiogenesis and alters cancer cell behavior, is implicated in inflammatory pathologies, autoimmune diseases and in many cancer processes such as cancer metastasis from gastrointestinal carcinoma, melanoma and lymphoma. This interaction is a promising target for the development of new therapeutic agents.

Three new cytotoxic 3,6-disubstituted indoles (Figure 15), with an isoprene unit at carbon 6, were isolated from Streptomyces strain BL-49-58-005 isolated from an unidentified marine invertebrate collected in México. These compounds are probably the products of different steps along the same biosynthetic pathway starting from tryptophan or tryptamine as presumed precursors. These indole compounds were assayed against a panel of 14 different tumor cell lines. Indole 1 (6-prenyltryptophol) showed the best activity against human leukemia K-562 cell line with a GI50 value of 8.46 μM. The aldoxime indole 2 showed activity with GI50 values within μM range against human prostate cancer LN-caP, endothelial cancer HMEC1, leukemia K-562, pancreatic carcinoma PANC1, and colon adenocarcinoma LOVO and LOVO-DOX cell lines. Nitrile indole 3 showed no activity. Streptochlorin (Figure 15) is a 3-substituted indole compound with antiangiogenic and anticancer activities produced by Streptomyces strain 04DH110 isolated from shallow water sediment taken at 1 m depth of Ayajin Bay, on the East Sea of Korea. Streptochlorin exhibited significant in vitro growth inhibitory activity against human leukemia K-562 cells with an IC50 of 1.05 μg/mL. The apoptosis effect induced by streptochlorin was investigated in human leukemic U937 and hepatocarcinoma Hep3B cells showing it was correlated with a decrease in the mitochondrial membrane potential, activation of caspase-3, and down-regulation of antiapoptotic Bcl-2 protein. Those effects were exerted through production of reactive oxygen species in Hep3B cells. In U937 cells up-regulation of pro-apoptotic Bax and FasL, and degradation of poly-(ADP-ribose)polymerase and phospholipase C-γ1 protein was also observed. Streptochlorin was found to have, in addition, a potent antiangiogenic activity by inhibition of endothelial cell invasion and tube formation stimulated with vascular endothelial cell growth factor, probably by inhibition of TNF-α-induced NF-κB activation.

Caboxamycin (Figure 15) is a benzoxazole compound produced by Streptomyces sp. NTK 937 isolated from an Atlantic Ocean deep-sea sediment collected in the Canary Basin. It was tested against different tumor cell lines and showed moderate growth inhibitory activity towards human gastric adenocarcimona AGS, hepatocellular carcinoma Hep G2 and breast carcinoma MCF7 cell lines with GI50 of 7.5, 7.4 and 7.3 μg/mL, respectively.

Streptokordin (Figure 15) is a methylpyridine compound produced by Streptomyces Sp. KORDI-3238 isolated from deep-sea sediments at Ayu Trough. It exhibited significant in vitro antitumor activity against human breast cancer MDA-MB-231, colon cancer HCT 15, prostate cancer PC-3, lung cancer NCI-H23, renal cancer ACHN, skin cancer LOX-IMVI and leukemia K-562 cell lines with IC50 values raging from 3.2 to 8.6 μg/mL. Streptokordin did not show inhibitory effect at the concentration of 1 mg/mL on the growth of any Gram-positive or -negative bacteria or fungus tested.

S. luteoverticillatum 11014 isolated from underwater sediment at 20 m depth collected off the coast of Taipingjiao, Qingdao, China, is the producer of four known butenolides: (4S)-4,10-dihydroxy-10-methyl-undec-2-en-1,4-olide, (4S)-4,10-dihydroxy-10-methyl-dodec-2-en-1,4-olide, and two diastereomeric (4S)-4,11-dihydroxy-10-methyl-dodec-2-en-1,4-olides (Figure 15). The four butenolides showed cytotoxic activity against human leukemia K562 with IC50 values of 8.73, 6.29, and 1.05 μmol/mL and murine lymphoma P388 cell lines with IC50 values of 0.34, 0.19, and 0.18 μmol/mL, respectively. The mixture of butenolides 3 and 4, (4S)-4,11-dihydroxy-10-methyl-dodec-2-en-1,4-olides, was the most active, but it was unknown if both of the diastereomers were active.

Actinomadura sp. M048 derived from sediments of Jiaozhou Bay in China is the producer of known phenazine compounds iodinin and 1,6-phenazinediol, the phenoxazin-3-one compounds questiomycin A and N-acetylquestiomycin A, and three new phenoxazin-3-one antibiotics chandrananimycins A, B and C (Figure 16). Questiomycins and chandrananimycins were found to be active against human colon carcinoma CCL HT29, melanoma MEXF 514L, lung carcinoma LXFA 526L and LXFL 529L, breast carcinoma CNCL SF268, LCL H460 and MACL MCF-7, prostate cancer PRCL PC3M and renal cancer RXF 631L cell lines with IC70 values down to 1.4 μg/mL. Iodinin and 1,6-phenazinediol exhibited antitumor activity against the human lung carcinoma LXFA 629L and LXFL 529L, breast cancer MAXF 401NL, melanoma MEXF 462NL, renal cancer RXF 944L and uterus cancer UXF 1138L cell lines with IC50 values of 3.6 and 3.2 μg/mL, respectively.

Echinosporin and 7-deoxyechinosporin (Figure 16), tricyclic acetal-lactones, are produced by S. albogriseolus A2002 isolated from a sea sediment sample collected in Jiaozhou Bay, China and have been previously described as produced by S. echinosporus MK-213 and by Sac. erythraea Tü 4015 (formerly S. erythraeus) where it was shown by feeding experiments that echinosporin is synthesized by the shikimate pathway with chorismate as a biosynthetic intermediate. Echinosporin was shown to inhibit the proliferation of human myelogenous leukemia K562, colon carcinoma HCT-15 and mouse mammary carcinoma tsFT210 cell lines in vitro, human breast adenocarcinoma MCF7, hepatocellular carcinoma Huh7 and HepG2 cell lines in vitro and on rodent tumor models such as leukemia P388, P388/VCR, and fibrosarcoma Meth 1 in vivo. 7-deoxyechinosporin showed a weaker effect than echinosporin on K562, HCT-15 and tsFT210 cell lines. Both compounds were shown to arrest the cell cycle of K562, HCT-15 and tsFT210 cells mainly at the G2/M phase and to induce apoptosis in these cells.

Apart of the antitumor compounds produced by marine actinomycetes depicted above, there are several additional compounds with antitumor activity like the topoisomerase I inhibitors cyclopropane and 14-methylhexadecanoic fatty acids produced by Streptomyces sp. strain KM86-913, isolated from a marine sponge collected under the seashore of Keomun Island, Korea. In other cases the compounds identified are yet uncharacterized as is the case of light-activated cytotoxic compounds produced by different microorganisms, including actinomycetes isolated from marine sponges collected from various places in the coast of Peninsular Malaysia.

8. Conclusions

Actinomycetes and, in particular the genus Streptomyces, have been well known during the last seventy years as prolific producers of new bioactive compounds, antitumor drugs included. With the increasing development of oceanographic studies leading to the isolation of new actinomycetes from marine sources, new prolific genera in the production of useful compounds have been found, such as Salinispora. However, the Ocean, without any doubt, is keeping a myriad of new actinomycetes providing novel structural diversity to be discovered and used. In addition, the continuous effort for unravel the biosynthesis of the already known compounds and the isolation and characterization of their biosynthesis gene clusters will lead to the development of new antitumor compounds, hopefully with improved therapeutic properties, by using combinatorial biosynthesis approaches.

References 185

  1. 1.

    Ventura M Canchaya C Tauch A Chandra G Fitzgerald GF Chater KF van Sinderen D Genomics of Actinobacteria: Tracing the evolutionary history of an ancient phylumMicrobiol Mol Biol Rev2007 71495548

    Not in our library10.1128/mmbr.00005-07

  2. 2.

    Goodfellow M Williams ST Ecology of actinomycetesAnnu Rev Microbiol1983 37189216

    Not in our library10.1146/annurev.mi.37.100183.001201

  3. 3.

    McCarthy AJ Williams ST Actinomycetes as agents of biodegradation in the environment-a reviewGene1992 115189192

    Not in our library10.1016/0378-1119(92)90558-7

  4. 4.

    Stach JE Bull AT Estimating and comparing the diversity of marine actinobacteriaAntonie van Leeuwenhoek2005 8739

    Not in our library10.1007/s10482-004-6524-1

  5. 5.

    Wilkins K Volatile metabolites from actinomycetesChemosphere1996 3214271434

    Not in our library

  6. 6.

    Schrempf H Recognition and degradation of chitin by streptomycetesAntonie van Leeuwenhoek2001 79285289

    Not in our library10.1023/a:1012058205158

  7. 7.

    Berdy J Bioactive microbial metabolitesJ Antibiot2005 58126

    Not in our library10.1038/ja.2005.1

  8. 8.

    Newman DJ Cragg GM Natural products as sources of new drugs over the last 25 yearsJ Nat Prod2007 70461477

    Not in our library10.1021/np068054v

  9. 9.

    Olano C Méndez C Salas JA Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesisNat Prod Rep2009 26628660

    Not in our library10.1039/b822528a

  10. 10.

    Demain AL Sánchez S Microbial drug discovery: 80 years of progressJ Antibiot2009 62516

    Not in our library10.1038/ja.2008.16

  11. 11.

    Baltz RH Renaissance in antibacterial discovery from actinomycetesCurr Opin Pharmacol2008 8557563

    Not in our library10.1016/j.coph.2008.04.008

  12. 12.

    Ghanem NB Sabry SA El-Sherif ZM Abu El-Ela GA Isolation and enumeration of marine actinomycetes from seawater and sediments in AlexandriaJ Gen Appl Microbiol2000 46105111

    Not in our library10.2323/jgam.46.105

  13. 13.

    Zheng Z Zeng W Huang Y Yang Z Li J Cai H Su W Detection of antitumor and antimicrobial activities in marine organism associated actinomycetes isolated from the Taiwan Strait, ChinaFEMS Microbiol Lett2000 1888791

    Not in our library10.1111/j.1574-6968.2000.tb09173.x

  14. 14.

    Fiedler HP Bruntner C Bull AT Ward AC Goodfellow M Potterat O Puder C Mihm G Marine actinomycetes as a source of novel secondary metabolitesAntonie van Leeuwenhoek2005 873742

    Not in our library10.1007/s10482-004-6538-8

  15. 15.

    Ward AC Bora N Diversity and biogeography of marine actinobacteriaCurr Opin Microbiol2006 918

    Not in our library10.1016/j.mib.2006.04.004

  16. 16.

    Fenical W Jensen PR Developing a new resource for drug discovery: marine actinomycete bacteriaNat Chem Biol2006 2666673

    Not in our library10.1038/nchembio841

  17. 17.

    Panthom-Aree W Stach JEM Ward AC Horikoshi K Bull AT Goodfellow M Diversity of actinomycetes isolated from challenger deep sediment (10,898 m) from the Mariana TrenchExtremophiles2006 10181189

    Not in our library10.1007/s00792-005-0482-z

  18. 18.

    Bull AT Stach JEM Marine actinobacteria: new opportunities for natural product search and discoveryTrends Microbiol2007 15491499

    Not in our library10.1016/j.tim.2007.10.004

  19. 19.

    Gontang EA Fenical W Jensen PR Phylogenetic diversity of Gram-positive bacteria cultured from marine sedimentsAppl Environ Microbiol2007 7332723282

    Not in our library10.1128/aem.02811-06

  20. 20.

    Bredholdt H Galatenko OA Engelhardt K Fjærvik E Terekhova LP Zotchev SB Rare actinomycete bacteria from the shallow water sediments of the Trodheim fjord, Norway: isolation, diversity and biological activityEnviron Microbiol2007 927562764

    Not in our library10.1111/j.1462-2920.2007.01387.x

  21. 21.

    Jensen PR Lauro FM An assessment of actinobacterial diversity in the marine environmentAntonie van Leeuwenhoek2008 945162

    Not in our library10.1007/s10482-008-9239-x

  22. 22.

    Anzai K Nakashima T Kuwahara N Suzuki R Ohfuku Y Takeshita S Ando K Actinomycete bacteria isolated from the sediments at coastal and offshore area of Nagasaki Prefecture, Japan: diversity and biological activityJ Biosci Bioeng2008 106215217

    Not in our library10.1263/jbb.106.215

  23. 23.
  24. 24.

    Maldonado LA Fragoso-Yánez D Pérez-García A Rosellón-Druker J Quintana ET Actinobacterial diversity from marine sediments collected in MéxicoAntonie van Leeuwenhoek2009 95111120

    Not in our library10.1007/s10482-008-9294-3

  25. 25.

    Bernan VS Greenstein M Carter GT Mining marine microorganisms as a source of new antimicrobials and antifungalsCurr Med Chem Anti-Infective Agents2004 3181195

    Not in our library

  26. 26.

    Piel J Metabolites from symbiotic bacteriaNat Prod Rep2004 21519538

    Not in our library10.1039/b310175b

  27. 27.

    Kim TK Fuerst JA Diversity of polyketide synthase genes from bacteria associated with the marine sponge Pseudoceratina clavata: culture-dependent and culture-independent approachesEnviron Microbiol2006 814601470

    Not in our library10.1111/j.1462-2920.2006.01040.x

  28. 28.

    Blunt JW Copp BR Munro MH Northcote PT Prinsep MR Marine natural productsNat Prod Rep2006 232678

    Not in our library10.1039/b502792f

  29. 29.

    Mayer AM Rodríguez AD Berlinck RG Hamann MT Marine pharmacology in 2003–4 Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of actionComp Biochem Physiol2007 145553581

    Not in our library10.1016/j.cbpc.2007.01.015

  30. 30.

    Williams PG Panning for chemical gold: marine bacteria as a source of new therapeuticsTrends Biotechnol2009 274552

    Not in our library10.1016/j.tibtech.2008.10.005

  31. 31.

    Blunt JW Copp BR Hu WP Munro MH Northcote PT Prinsep MR Marine natural productsNat Prod Rep2009 26170244

    Not in our library10.1039/b805113p

  32. 32.

    Fenical W Sethna KM Lloyd GK Marine microorganisms as a developing resource for drug discoveryPharm News2002 9489494

    Not in our library

  33. 33.

    Tsueng G Teisan S Lam KS Defined salt formulations for the growth of Salinispora tropica strain NPS21184 and the production of salinosporamide A (NPI-0052) and related analogsAppl Microbiol Biotechnol2008 78827832

    Not in our library10.1007/s00253-008-1358-9

  34. 34.

    Janssen PH Yates PS Grinton BE Taylor PM Sait M Improved culturability of soil bacteria and isolation in pure culture of novel members of the divisions Acidobacteria, Actinobacteria, Proteobacteria, andVerrucomicrobia Appl Environ Microbiol2002 6823912396

    Not in our library10.1128/aem.68.5.2391-2396.2002

  35. 35.

    Donadio S Monciardini P Alduina R Mazza P Chiocchini C Cavaletti L Sosio M Puglia AM Microbial technologies for the discovery of novel bioactive metabolitesJ Biotechnol2002 99187198

    Not in our library10.1016/s0168-1656(02)00209-2

  36. 36.

    Bull AT Stach JE Marine actinobacteria: new opportunities for natural product search and discoveryTrends Microbiol2007 15491499

    Not in our library10.1016/j.tim.2007.10.004

  37. 37.

    Bull AT Stach JE Ward AC Goodfellow M Marine actinobacteria: perspectives, challenges, future directionsAntonie van Leeuwenhoek2005 876579

    Not in our library

  38. 38.

    Lam KS Tsueng G McArthur KA Mitchell SS Potts BC Xu J Effects of halogens on the production of salinosporamides by the obligate marine actinomycete Salinispora tropicaJ Antibiot2007 601319

    Not in our library10.1038/ja.2007.2

  39. 39.

    Selvin J Shanmughapriya S Gandhimathi R Seghal Kiran G Rajeetha Ravji T Natarajaseenivasan K Hema TA Optimization and production of novel antimicrobial agents from sponge associated marine actinomycetes Nocardiopsis dassonvillei MAD08Appl Microbiol Biotechnol2009 83435445

    Not in our library10.1007/s00253-009-1878-y

  40. 40.

    Moore BS Kalaitzis JA Xiang L Exploiting marine actinomycete biosynthetic pathways for drug discoveryAntonie van Leeuwenhoek2005 874957

    Not in our library10.1007/s10482-004-6541-0

  41. 41.

    Hou YH Wang QF Ding L Li FC Qin S attB site disruption in marine Actinomyces sp. M048 via DNA transformation of a site-specific integration vectorBiotechnol Appl Biochem2008 501116

    Not in our library10.1042/ba20070124

  42. 42.

    Shen B Polyketide biosynthesis beyond the type I, II and III polyketide synthase paradigmsCurr Opin Chem Biol2003 7285295

    Not in our library10.1016/s1367-5931(03)00020-6

  43. 43.

    Gokhale RS Sankaranarayanan R Mohanty D Versatility of polyketide synthases in generating metabolic diversityCurr Opin Struct Biol2007 17736743

    Not in our library10.1016/j.sbi.2007.08.021

  44. 44.

    Williams PG Miller ED Asolkar RN Jensen PR Fenical W Arenicolides A-C, 26-membered ring macrolides from the marine actinomycete Salinispora arenicolaJ Org Chem2007 7250255034

    Not in our library10.1021/jo061878x

  45. 45.

    Williams PG Asolkar RN Kondratyuk T Pezzuto JM Jensen PR Fenical W Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicolaJ Nat Prod2007 708388

    Not in our library10.1021/np0604580

  46. 46.

    Gerner EW Meyskens FL Jr Polyamines and cancer: old molecules, new understandingNat Rev Cancer2004 4781792

    Not in our library10.1038/nrc1454

  47. 47.

    Cañedo LM Fernández-Puentes JL Baz JP IB-96212, a novel cytotoxic macrolide produced by a marine MicromonosporaII Physico-chemical properties and structure determinationJ. Antibiot2000 53479483

    Not in our library10.7164/antibiotics.53.479

  48. 48.

    Fernández-Chimeno RI Cañedo L Espliego F Grávalos D De La Calle F Fernández-Puentes JL Romero F IB-96212, a novel cytotoxic macrolide produced by a marine MicromonosporaI Taxonomy, fermentation, isolation and biological activities J Antibiot2000 53474478

    Not in our library10.7164/antibiotics.53.474

  49. 49.

    Wu SJ Fotso S Li F Qin S Laatsch H Amorphane sesquiterpenes from a marine Streptomyces spJ Nat Prod2007 70304306

    Not in our library10.1021/np050358e

  50. 50.

    Asolkar RN Maskey RP Helmke E Laatsch H Chalcomycin B, a new macrolide antibiotic from the marine isolate Streptomyces sp. B7064J. Antibiot2002 55893898

    Not in our library10.7164/antibiotics.55.893

  51. 51.

    Gupta RS Murray W Gupta R Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell lineBr J Cancer1988 58441447

    Not in our library10.1038/bjc.1988.237

  52. 52.

    Ward SL Hu Z Schirmer A Reid R Revill WP Reeves CD Petrakovsky OV Dong SD Katz L Chalcomycin biosynthesis gene cluster from Streptomyces bikiniensis: novel features of an unusual ketolide produced through expression of the chm polyketide synthase in Streptomyces fradiaeAntimicrob Agents Chemother2004 4847034712

    Not in our library10.1128/aac.48.12.4703-4712.2004

  53. 53.

    Mitchell SS Nicholson B Teisan S Lam KS Potts BC Aureoverticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatusJ Nat Prod2004 6714001402

    Not in our library10.1021/np049970g

  54. 54.

    Kwon HC Kauffman CA Jensen PR Fenical W Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus “Marinispora”J Am Chem Soc2006 12816221632

    Not in our library10.1021/ja0558948

  55. 55.

    Hara M Akasaka K Akinaga S Okabe M Nakano H Gomez R Wood D Uh M Tamanoi F Identification of Ras farnesyltransferase inhibitors by microbial screeningProc Natl Acad Sci USA1993 9022812285

    Not in our library10.1073/pnas.90.6.2281

  56. 56.

    Sattler I Thiericke R Zeeck A The manumycin-group metabolitesNat Prod Rep1998 15221240

    Not in our library10.1039/a815221y

  57. 57.

    Li F Maskey RP Qin S Sattler I Fiebig HH Maier A Zeeck A Laatsch H Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045J Nat Prod2005 68349353

    Not in our library10.1021/np030518r

  58. 58.

    Asolkar RN Jensen PR Kauffman CA Fenical W Daryamides A-C, weakly cytotoxic polyketides from a marine-derived actinomycete of the genus Streptomyces strain CNQ-085J Nat Prod2006 6917561759

    Not in our library10.1021/np0603828

  59. 59.

    Davidson B Ireland CM Lissoclinolide, the first non-nitrogenous metabolite from a Lissoclinum tunicateJ Nat Prod1990 5310361038

    Not in our library10.1021/np50070a049

  60. 60.

    Gallo GG Coronelli C Vigevani A Lancini GC The structure of tetrenolin: a new antibiotic substanceTetrahedron1969 2556775680

    Not in our library10.1016/s0040-4020(01)83074-x

  61. 61.

    Pagani H Lancini G Tamoni G Coronelli C Tetrenolin and SS/1018 A, antibacterial agents isolated from a strain of actinomycetalesJ Antibiot1973 2616

    Not in our library10.7164/antibiotics.26.1

  62. 62.

    Richardson AD Ireland CM A profile of the in vitro antitumor activity of lissoclinolideToxicol Appl Pharmacol2004 1955561

    Not in our library10.1016/j.taap.2003.10.004

  63. 63.

    Oh DC Gontang EA Kauffman CA Jensen PR Fenical W Salinipyrones and pacificanones, mixed-precursor polyketides from the marine actinomycete Salinispora pacificaJ Nat Prod2008 71570575

    Not in our library10.1021/np0705155

  64. 64.

    Buchanan GO Williams PG Feling RH Kauffman CA Jensen PR Fenical W Sporolides A and B: structurally unprecedented halogenated macrolides from the marine actinomycete Salinispora tropicaOrg Lett2005 727312734

    Not in our library10.1021/ol050901i

  65. 65.

    Cho JY Kwon HC Williams PG Kauffman CA Jensen PR Fenical W Actinofuranones A and B, polyketides from a marine-derived bacterium related to the genus Streptomyces (actinomycetales)J Nat Prod2006 69425428

    Not in our library10.1021/np050402q

  66. 66.

    Oh DC Williams PG Kauffman CA Jensen PR Fenical W Cyanosporasides A and B, chloro- and cyano-cyclopenta[a]indene glycosides from the marine actinomycete “Salinispora pacifica”Org Lett2006 810211024

    Not in our library10.1021/ol052686b

  67. 67.

    Hayakawa Y Shirasaki S Kawasaki T Matsuo Y Adachi K Shizuri Y Structures of new cytotoxic antibiotics, piericidins C7 and C8J Antibiot2007 60201203

    Not in our library10.1038/ja.2007.23

  68. 68.

    Morgenbesser SD Williams BO Jacks T DePinho RA p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lensNature1994 3717274

    Not in our library10.1038/371072a0

  69. 69.

    Hayakawa Y Shirasaki S Shiba S Kawasaki T Matsuo Y Adachi K Shizuri Y Piericidins C7 and C8, new cytotoxic antibiotics produced by a marine Streptomyces spJ Antibiot2007 60196200

    Not in our library10.1038/ja.2007.22

  70. 70.

    Jeong SY Shin HJ Kim TS Lee HS Park SK Kim HM Streptokordin, a new cytotoxic compound of the methylpyridine class from a marine-derived Streptomyces sp. KORDI-3238J. Antibiot2006 59234240

    Not in our library10.1038/ja.2006.33

  71. 71.

    Smith WC Xiang L Shen B Genetic localization and molecular characterization of the nonS gene required for macrotetrolide biosynthesis in Streptomyces griseus DSM40695Antimicrob Agents Chemother2000 4418091817

    Not in our library10.1128/aac.44.7.1809-1817.2000

  72. 72.

    Borrel MN Pereira E Fiallo M Garnier-Suillerot A Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4′-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cellsEur J Biochem1994 223125133

    Not in our library10.1111/j.1432-1033.1994.tb18973.x

  73. 73.

    Itoh T Kinoshita M Wei H Kobayashi M Stereostructure of komodoquinone A, a neuritogenic anthracycline, from marine Streptomyces sp. KS3Chem Pharm Bull2003 5114021404

    Not in our library10.1248/cpb.51.1402

  74. 74.

    Itoh T Kinoshita M Aoki S Kobayashi M Komodoquinone A, a novel neuritogenic anthracycline, from marine Streptomyces sp. KS3J Nat Prod2003 6613731377

    Not in our library10.1021/np030212k

  75. 75.

    Wu SJ Fotso S Li F Qin S Kelter G Fiebig HH Laatsch H 39-N-carboxamido-staurosporine and selina-4(14),7(11)-diene-8,9-diol, new metabolites from a marine Streptomyces spJ Antibiot2006 59331337

    Not in our library10.1038/ja.2006.46

  76. 76.

    Butler MS Natural products to drugs: natural product-derived compounds in clinical trialsNat Prod Rep2008 25475516

    Not in our library10.1039/b514294f

  77. 77.

    Xu Z Jakobi K Welzel K Hertweck C Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyketideChem Biol2005 12579588

    Not in our library10.1016/j.chembiol.2005.04.017

  78. 78.

    Lorico A Long BH Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase IIEur J Cancer1993 29A19851991

    Not in our library10.1016/0959-8049(93)90459-s

  79. 79.

    McGovren JP Neil GL Crampton SL Robinson MI Douros JD Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159)Cancer Res1977 3716661672

    Not in our library

  80. 80.

    Maskey RP Helmke E Laatsch H Himalomycin A and B: isolation and structure elucidation of new fridamycin type antibiotics from a marine Streptomyces isolateJ Antibiot2003 56 942949

    Not in our library10.7164/antibiotics.56.942

  81. 81.

    Masuma R Tanaka K New antitumor antibiotics, OS-4742 A1, A2, B1 and B2 produced by a strain ofStreptomyces J Antibiot1977 30908916

    Not in our library10.7164/antibiotics.30.908

  82. 82.

    Maskey RP Helmke E Fiebig HH Laatsch H Parimycin: isolation and structure elucidation of a novel cytotoxic 2,3-dihydroquinizarin analogue of gamma-indomycinone from a marine streptomycete isolateJ Antibiot2002 5510311035

    Not in our library10.7164/antibiotics.55.1031

  83. 83.

    Maskey RP Helmke E Kayser O Fiebig HH Maier A Busche A Laatsch H Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine streptomycete and their absolute stereochemistryJ Antibiot2004 57771779

    Not in our library10.7164/antibiotics.57.771

  84. 84.

    Maskey RP Sevvana M Usón I Helmke E Laatsch H Gutingimycin: a highly complex metabolite from a marine streptomyceteAngew Chem Int Ed Engl2004 4312811283

    Not in our library10.1002/anie.200352312

  85. 85.

    Fitzner A Frauendorf H Laatsch H Diederichsen U Formation of gutingimycin: analytical investigation of trioxacarcin A-mediated alkylation of dsDNAAnal Bioanal Chem2008 39011391147

    Not in our library10.1007/s00216-007-1737-6

  86. 86.

    Huang YF Tian L Fu HW Hua HM Pei YH One new anthraquinone from marine Streptomyces sp. FX-58Nat Prod Res2006 2012071210

    Not in our library10.1080/14786410600899142

  87. 87.

    Gorajana A Kurada BV Peela S Jangam P Vinjamuri S Poluri E Zeeck A 1-Hydroxy-1-norresistomycin, a new cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7J Antibiot2005 58526529

    Not in our library10.1038/ja.2005.72

  88. 88.

    Kock I Maskey RP Biabani MA Helmke E Laatsch H 1-Hydroxy-1-norresistomycin and resistoflavin methyl ether: new antibiotics from marine-derived streptomycetesJ Antibiot2005 58530534

    Not in our library10.1038/ja.2005.73

  89. 89.

    Martin P Rodier S Mondon M Renoux B Pfeiffer B Renard P Pierre A Gesson JP Synthesis and cytotoxic activity of tetracenomycin D and of saintopin analoguesBioorg Med Chem2001 10253260

    Not in our library10.1016/s0968-0896(01)00273-5

  90. 90.

    Hutchinson CR Biosynthetic studies of daunorubicin and tetracenomycin CChem Rev1997 9725252536

    Not in our library10.1021/cr960022x

  91. 91.

    Shiono Y Shiono N Seo S Oka S Yamazaki Y Effects of polyphenolic anthrone derivatives, resistomycin and hypercin, on apoptosis in human megakaryoblastic leukemia CMK-7 cell lineZ Naturforsch2002 57923929

    Not in our library10.1515/znc-2002-9-1028

  92. 92.

    Jakobi K Hertweck C A gene cluster encoding resistomycin biosynthesis in Streptomyces resistomycificus; exploring polyketide cyclization beyond linear and angucyclic patternsJ Am Chem Soc2004 12622982289

    Not in our library10.1021/ja0390698

  93. 93.

    Gorajana A Venkatesan M Vinjamuri S Kurada BV Peela S Jangam P Poluri E Zeeck A Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7Microbiol Res2007 162322327

    Not in our library10.1016/j.micres.2006.01.012

  94. 94.

    Martin GD Tan LT Jensen PR Dimayuga RE Fairchild CR Raventos-Suarez C Fenical W Marmycins A and B, cytotoxic pentacyclic C-glycosides from a marine sediment-derived actinomycete related to the genus StreptomycesJ Nat Prod2007 7014061409

    Not in our library10.1021/np060621r

  95. 95.

    Imamura N Kakinuma K Ikekawa N Tanaka H Omura S Biosynthesis of vineomycins A1 and B2J Antibiot1982 37602607

    Not in our library10.7164/antibiotics.35.602

  96. 96.

    Kitahara T Naganawa H Okazaki T Okami Y Umezawa H The structure of SS-228 Y, an antibiotic from Chainia spJ Antibiot1975 28280285

    Not in our library

  97. 97.

    Okazaki T Kitahara T Okami Y Studies on marine microorganisms. IV. A new antibiotic SS-228 Y produced by Chainia isolated from shallow sea mudJ Antibiot1975 28176184

    Not in our library10.7164/antibiotics.28.176

  98. 98.

    Malet-Cascón L Romero F Espliego-Vázquez F Grávalos D Fernández-Puentes JL IB-00208, a new cytotoxic polycyclic xanthone produced by a marine-derived Actinomadura. I. Isolation of the strain, taxonomy and biological activitesJ Antibiot2003 56219225

    Not in our library10.7164/antibiotics.56.219

  99. 99.

    Rodríguez JC Fernández-Puentes JL Baz JP Canedo LM IB-00208, a new cytotoxic polycyclic xanthone produced by a marine-derived Actinomadura. II. Isolation, physico-chemical properties and structure determinationJ Antibiot2003 56318321

    Not in our library10.7164/antibiotics.56.318

  100. 100.

    Tresselt D Eckardt K Ihn W Antibiotics from Actinomycetes - chemical composition of antibiotic griseorhodin ATetrahedron1978 34 26932699

    Not in our library

  101. 101.

    Ueno T Takahashi H Oda M Mizunuma M Yokoyama A Goto Y Mizushina Y Sakaguchi K Hayashi H Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moietyBiochemistry2000 3959956002

    Not in our library10.1021/bi992661i

  102. 102.

    Shay JW Zou Y Hiyama E Wright WE Telomerase and cancerHum Mol Genet2001 10677685

    Not in our library10.1093/hmg/10.7.677

  103. 103.

    Li A Piel J A gene cluster from a marine Streptomyces encoding the biosynthesis of the aromatic spiroketal polyketide griseorhodin AChem Biol2002 910171026

    Not in our library10.1016/s1074-5521(02)00223-5

  104. 104.

    Walsh CT Polyketide and nonribosomal peptide antibiotics: modularity and versatilityScience2004 30318051810

    Not in our library10.1126/science.1094318

  105. 105.

    Sieber SA Marahiel MA Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibioticsChem Rev2005 105715738

    Not in our library10.1021/cr0301191

  106. 106.

    Fischbach MA Walsh CT Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanismsChem Rev2006 10634683496

    Not in our library10.1021/cr0503097

  107. 107.

    Fiedler HP Bruntner C Riedlinger J Bull AT Knutsen G Goodfellow M Jones A Maldonado L Pathom-aree W Beil W Schneider K Keller S Sussmuth RD Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete VerrucosisporaJ Antibiot2008 61158163

    Not in our library10.1038/ja.2008.125

  108. 108.

    Riedlinger J Reicke A Zähner H Krismer B Bull AT Maldonado LA Ward AC Goodfellow M Bister B Bischoff D Süssmuth RD Fiedler HP Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucosispora strain AB-18-032J Antibiot2004 57271279

    Not in our library10.7164/antibiotics.57.271

  109. 109.

    Schneider K Keller S Wolter FE Röglin L Beil W Seitz O Nicholson G Bruntner C Riedlinger J Fiedler HP Süssmuth RD Proximicins A, B, and C-antitumor furan analogues of netropsin from the marine actinomycete Verrucosispora induce upregulation of p53 and the cyclin kinase inhibitor p21Angew Chem Int Ed Engl2008 4732583261

    Not in our library10.1002/anie.200705295

  110. 110.

    Cho JY Williams PG Kwon HC Jensen PR Fenical W Lucentamycins A-D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensisJ Nat Prod2007 7013211328

    Not in our library10.1021/np070101b

  111. 111.

    Kanoh K Matsuo Y Adachi K Imagawa H Nishizawa M Shizuri Y Mechercharmycins A and B, cytotoxic substances from marine-derived Thermoactinomyces sp. YM3-251J Antibiot2005 58289292

    Not in our library10.1038/ja.2005.36

  112. 112.

    Romero F Espliego F Pérez Baz J García de Quesada T Grávalos D de la Calle F Fernández-Puentes JL Thiocoraline, a new depsipeptide with antitumor activity produced by a marine Micromonospora. I. Taxonomy, fermentation, isolation, and biological activitiesJ Antibiot1997 50734737

    Not in our library10.7164/antibiotics.50.734

  113. 113.

    Pérez Baz J Canedo LM Fernández Puentes JL Silva Elipe MV Thiocoraline, a novel depsipeptide with antitumor activity produced by a marine Micromonospora. II. Physico-chemical properties and structure determinationJ Antibiot1997 50738741

    Not in our library10.7164/antibiotics.50.738

  114. 114.

    Erba E Bergamaschi D Ronzoni S Faretta M Taverna S Bonfanti M Catapano CV Faircloth G Jimeno J D’Incalci M Mode of action of thiocoraline, a natural marine compound with anti-tumour activityBr J Cancer1999 80971980

    Not in our library10.1038/sj.bjc.6690451

  115. 115.

    Dawson S Malkinson JP Paumier D Searcey M Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studiesNat Prod Rep2007 24109126

    Not in our library10.1039/b516347c

  116. 116.

    Lombó F Velasco A Castro A de la Calle F Brana AF Sánchez-Puelles JM Méndez C Salas JA Deciphering the biosynthesis pathway of the antitumor thiocoraline from a marine actinomycete and its expression in two Streptomyces speciesChemBioChem2006 7366376

    Not in our library10.1002/cbic.200500325

  117. 117.

    Asolkar RN Freel KC Jensen PR Fenical W Kondratyuk TP Park EJ Pezzuto JM Arenamides A-C, cytotoxic NF-κB inhibitors from the marine actinomycete Salinispora arenicolaJ Nat Prod2009 72396402

    Not in our library10.1021/np800617a

  118. 118.

    Aggarwal BB Sethi G Nair A Ichikawa H Nuclear factor-κB A holy grail in cancer prevention and therapyCurr Signal Transduction Ther2006 12552

    Not in our library

  119. 119.

    Melisi D Chiao PJ NF-κB as a target for cancer therapyExpert Opin Ther Targets2007 11133144

    Not in our library10.1517/14728222.11.2.133

  120. 120.

    Miller ED Kauffman CA Jensen PR Fenical W Piperazimycins: cytotoxic hexadepsipeptides from a marine-derived bacterium of the genusStreptomyces J Org Chem2007 72323330

    Not in our library10.1021/jo061064g

  121. 121.

    Feling RH Buchanan GO Mincer TJ Kauffman CA Jensen PR Fenical W Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus SalinosporaAngew Chem Int Ed Engl2003 42355357

    Not in our library10.1002/anie.200390115

  122. 122.

    Udwary DW Zeigler L Asolkar RN Singan V Lapidus A Fenical W Jensen PR Moore BS Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropicaProc Natl Acad Sci USA2007 1041037610381

    Not in our library10.1073/pnas.0700962104

  123. 123.

    Jensen PR Williams PG Oh DC Zeigler L Fenical W Species-specific secondary metabolite production in marine actinomycetes of the genus SalinisporaAppl Environ Microbiol2007 7311461152

    Not in our library10.1128/aem.01891-06

  124. 124.

    Miller CP Ban K Dujka ME McConkey DJ Munsell M Palladino M Chandra J NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cellsBlood2007 110267277

    Not in our library10.1182/blood-2006-03-013128

  125. 125.

    Beer LL Moore BS Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropicaOrg Lett2007 9845848

    Not in our library10.1021/ol063102o

  126. 126.

    Williams PG Buchanan GO Feling RH Kauffman CA Jensen PR Fenical W New cytotoxic salinosporamides from the marine actinomycete Salinispora tropicaJ Org Chem2005 7061966203

    Not in our library10.1021/jo050511+

  127. 127.

    Reed KA Manam RR Mitchell SS Xu J Teisan S Chao TH Deyanat-Yazdi G Neuteboom ST Lam KS Potts BC Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasomeJ Nat Prod2007 70269276

    Not in our library10.1021/np0603471

  128. 128.

    Lam KS Tsueng G McArthur KA Mitchell SS Potts BC Xu J Effects of halogens on the production of salinosporamides by the obligate marine actinomycete Salinispora tropicaJ Antibiot2007 601319

    Not in our library10.1038/ja.2007.2

  129. 129.

    Eustáquio AS Moore BS Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasomeAngew Chem Int Ed Engl2008 4739363938

    Not in our library10.1002/anie.200800177

  130. 130.

    McGlinchey RP Nett M Eustáquio AS Asolkar RN Fenical W Moore BS Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitorsJ Am Chem Soc2008 13078227823

    Not in our library10.1021/ja8029398

  131. 131.

    Manam RR Macherla VR Tsueng G Dring CW Weiss J Neuteboom ST Lam KS Potts BC Antiprotealide is a natural productJ Nat Prod2009 72295297

    Not in our library10.1021/np800578e

  132. 132.

    Manam RR Teisan S White DJ Nicholson B Grodberg J Neuteboom ST Lam KS Mosca DA Lloyd GK Potts BC Lajollamycin, a nitro-tetraene spiro-beta-lactone-gamma-lactam antibiotic from the marine actinomycete Streptomyces nodosusJ Nat Prod2005 68240243

    Not in our library10.1021/np049725x

  133. 133.

    Zhao C Ju J Christenson SD Smith WC Song D Zhou X Shen B Deng Z Utilization of the methoxymalonyl-acyl carrier protein biosynthesis locus for cloning the oxazolomycin biosynthetic gene cluster from Streptomyces albus JA3453J. Bacteriol2006 18841424147

    Not in our library10.1128/jb.00173-06

  134. 134.

    Dairi T Studies on biosynthetic genes and enzymes of isoprenoids produced by actinomycetesJ Antibiot2005 58227243

    Not in our library10.1038/ja.2005.27

  135. 135.

    Takahashi A Ikeda D Nakamura H Naganawa H Kurasawa S Okami Y Takeuchi T Iitaka Y Altemicidin, a new acaricidal and antitumor substance. II. Structure determinationJ Antibiot1989 4215621566

    Not in our library10.7164/antibiotics.42.1562

  136. 136.

    Takahashi A Kurasawa S Ikeda D Okami Y Takeuchi T Altemicidin, a new acaricidal and antitumor substance. I. Taxonomy, fermentation, isolation and physico-chemical and biological propertiesJ Antibiot1989 4215561561

    Not in our library10.7164/antibiotics.42.1556

  137. 137.

    Pathirana C Jensen PR Fenical W Marinone and debromomarinone: Antibiotic sesquiterpenoid naphthoquinones of a new structure class from a marine bacteriumTetrahedron Lett1992 3376637666

    Not in our library

  138. 138.

    Hardt IH Jensen PR Fenical W Neomarinone, and new cytotoxic marinone derivatives, produced by a marine filamentous bacterium (actinomycetales)Tetrahedron Lett2000 4120732076

    Not in our library

  139. 139.

    Kalaitzis JA Hamano Y Nilsen G Moore BS Biosynthesis and structural revision of neomarinoneOrg Lett2003 544494452

    Not in our library10.1021/ol035748b

  140. 140.

    Ding L Pfoh R Rühl S Qin S Laatsch H T-muurolol sesquiterpenes from the marine Streptomyces sp. M491 and revision of the configuration of previously reported amorphanesJ Nat Prod2009 7299101

    Not in our library10.1021/np8006843

  141. 141.

    Soria-Mercado IE Prieto-Davo A Jensen PR Fenical W Antibiotic terpenoid chloro-dihydroquinones from a new marine actinomyceteJ Nat Prod2005 68904910

    Not in our library10.1021/np058011z

  142. 142.

    Fukuda DS Mynderse JS Baker PJ Berry DM Boeck LD Yao RC Mertz FP Nakatsukasa WM Mabe J Ott J Counter FT Ensminger PW Allen NE Alborn WE Hobbs JN A80915, a new antibiotic complex produced by Streptomyces aculeolatus. Discovery, taxonomy, fermentation, isolation, characterization, and antibacterial evaluationJ Antibiot1990 43623633

    Not in our library10.7164/antibiotics.43.623

  143. 143.

    Saha M Jaisankar P Das S Sarkar KK Roy S Besra SE Vedasiromani JR Ghosh D Sana B Mukherjee J Production and purification of a bioactive substance inhibiting multiple drug resistant bacteria and human leukemia cells from a salt-tolerant marine Actinobacterium sp. isolated from the Bay of BengalBiotechnol Lett2006 2810831088

    Not in our library10.1007/s10529-006-9054-2

  144. 144.

    Sánchez C Méndez C Salas JA Indolocarbazole natural products: occurrence, biosynthesis, and biological activityNat Prod Rep2006 2310071045

    Not in our library10.1039/b601930g

  145. 145.

    Omura S Iwai Y Hirano A Nakagawa A Awaya J Tsuchya H Takahashi Y Masuma R A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterizationJ Antibiot1977 30275282

    Not in our library10.7164/antibiotics.30.275

  146. 146.

    Onaka H Taniguchi S Igarashi Y Furumai T Cloning of the staurosporine biosynthetic gene cluster from Streptomyces sp. TP-A0274 and its heterologous expression in Streptomyces lividansJ Antibiot2002 5510631071

    Not in our library10.7164/antibiotics.55.1063

  147. 147.

    Salas AP Zhu L Sánchez C Brana AF Rohr J Méndez C Salas JA Deciphering the late steps in the biosynthesis of the anti-tumour indolocarbazole staurosporine: sugar donor substrate flexibility of the StaG glycosyltransferaseMol Microbiol2005 581727

    Not in our library10.1111/j.1365-2958.2005.04777.x

  148. 148.

    Sánchez C Méndez C Salas JA Engineering biosynthetic pathways to generate antitumor indolocarbazole derivativesJ Ind Microbiol Biotechnol2006 33560568

    Not in our library10.1007/s10295-006-0092-5

  149. 149.

    Sánchez C Zhu L Brana AF Salas AP Rohr J Méndez C Salas JA Combinatorial biosynthesis of antitumor indolocarbazole compoundsProc Natl Acad Sci USA2005 102461466

    Not in our library10.1073/pnas.0407809102

  150. 150.

    Salas JA Méndez C Indolocarbazole antitumour compounds by combinatorial biosynthesisCurr Opin Chem Biol2009 13152160

    Not in our library10.1016/j.cbpa.2009.02.003

  151. 151.

    Hernández LM Blanco JA Baz JP Puentes JL Millán FR Vázquez FE Fernández-Chimeno RI Grávalos DG 4′-N-methyl-5′-hydroxystaurosporine and 5′-hydroxystaurosporine, new indolocarbazole alkaloids from a marine Micromonospora sp. strainJ Antibiot2000 53895902

    Not in our library10.7164/antibiotics.53.895

  152. 152.

    Han X Cui C Gu Q Zhu W Liu H Gu J Osada H ZHD-0501, a novel naturally occurring staurosporine analog from Actinomadura sp. 007Tetrahedron Lett2005 4661376140

    Not in our library

  153. 153.

    Liu R Zhu T Li D Gu J Xia W Fang Y Liu H Zhu W Gu Q Two indolocarbazole alkaloids with apoptosis activity from a marine-derived actinomycete Z2039-2Arch Pharm Res2007 30270274

    Not in our library10.1007/bf02977605

  154. 154.

    Robey RW Shukla S Steadman K Obrzut T Finley EM Ambudkar SV Bates SE Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structureMol Cancer Ther2007 618771885

    Not in our library10.1158/1535-7163.mct-06-0811

  155. 155.

    McArthur KA Mitchell SS Tsueng G Rheingold A White DJ Grodberg J Lam KS Potts BC Lynamicins A-E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomyceteJ Nat Prod2008 7117321737

    Not in our library10.1021/np800286d

  156. 156.

    Boonlarppradab C Kauffman CA Jensen PR Fenical W Marineosins A and B, cytotoxic spiroaminals from a marine-derived actinomyceteOrg Lett2008 1055055508

    Not in our library10.1021/ol8020644

  157. 157.

    Liu R Cui CB Duan L Gu QQ Zhu WM Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. novArch Pharm Res2005 2813411344

    Not in our library10.1007/bf02977899

  158. 158.

    Wasserman HH Rodgers GC Keith DD Metacycloprodigiosin, a tripyrrole pigment from Streptomyces longisporusruberJ Am Chem Soc1969 9112631264

    Not in our library10.1021/ja01033a065

  159. 159.

    Wasserman HH Keith DD Rodgers GC The structure of metacycloprodigiosinTetrahedron1976 3218551861

    Not in our library

  160. 160.

    Pérez-Tomás R Montaner B Llagostera E Soto-Cerrato V The prodigiosins, proapoptotic drugs with anticancer propertiesBiochem Pharmacol2003 6614471452

    Not in our library10.1016/s0006-2952(03)00496-9

  161. 161.

    Shin HJ Kim TS Lee HS Park JY Choi IK Kwon HJ Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973Phytochemistry2008 6923632366

    Not in our library10.1016/j.phytochem.2008.05.020

  162. 162.

    Hughes CC MacMillan JB Gaudêncio SP Jensen PR Fenical W The ammosamides: structures of cell cycle modulators from a marine-derived Streptomyces speciesAngew Chem Int Ed Engl2009 48725727

    Not in our library10.1002/anie.200804890

  163. 163.

    Bugni TS Woolery M Kauffman CA Jensen PR Fenical W Bohemamines from a marine-derived Streptomyces spJ Nat Prod2006 6916261628

    Not in our library10.1021/np0602721

  164. 164.

    Zhang Q Schrader KK ElSohly HN Takamatsu S New cell-cell adhesion inhibitors from Streptomyces sp. UMA-044J Antibiot2003 56673681

    Not in our library10.7164/antibiotics.56.673

  165. 165.

    Zimmerman T Blanco FJ Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of actionCurr Pharm Des2008 1421282139

    Not in our library10.2174/138161208785740225

  166. 166.

    Cossío FP Mendoza ML Zubia A Valcárcel M Vara YI Solaun MS López JJ San Sebastian E Novel inhibitors of the LFA-1/ICAM-1 interaction, and uses thereofWIPO Patent WO/2007/0541282007

    Not in our library

  167. 167.

    Sánchez López JM Martínez Insua M Pérez Baz J Fernández Puentes JL Canedo Hernández LM New cytotoxic indolic metabolites from a marine StreptomycesJ Nat Prod2003 66863864

    Not in our library10.1021/np0204444

  168. 168.

    Shin HJ Jeong HS Lee HS Park SK Kim HM Kwon HJ Isolation and structure determination of streptochlorin, an antiproliferative agent from a marine-derived Streptomyces sp. 04DH110J Microbiol Biotechnol2007 1714031406

    Not in our library

  169. 169.

    Park C Shin HJ Kim GY Kwon TK Nam TJ Kim SK Cheong J Choi IW Choi YH Induction of apoptosis by streptochlorin isolated from Streptomyces sp. in human leukemic U937 cellsToxicol In Vitro2008 2215731581

    Not in our library10.1016/j.tiv.2008.06.010

  170. 170.

    Shin DY Shin HJ Kim GY Cheong J Choi IW Kim SK Moon SK Kang HS Choi YH Streptochlorin isolated from Streptomyces sp. Induces apoptosis in human hepatocarcinoma cells through a reactive oxygen species-mediated mitochondrial pathwayJ Microbiol Biotechnol2008 1818621868

    Not in our library10.4014/jmb.0800.124

  171. 171.

    Choi IK Shin HJ Lee HS Kwon HJ Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitroJ. Microbiol. Biotechnol2007 1713381343

    Not in our library

  172. 172.

    Hohmann C Schneider K Bruntner C Irran E Nicholson G Bull AT Jones AL Brown R Stach JE Goodfellow M Beil W Krämer M Imhoff JF Süssmuth RD Fiedler HP Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937J Antibiot2009 6299104

    Not in our library10.1038/ja.2008.24

  173. 173.

    Li DH Zhu TJ Liu HB Fang YC Gu QQ Zhu WM Four butenolides are novel cytotoxic compounds isolated from the marine-derived bacterium, Streptoverticillium luteoverticillatum11014Arch Pharm Res2006 29624626

    Not in our library10.1007/bf02968245

  174. 174.

    Cho KW Lee HS Rho JR Kim TS Mo SJ Shin J New lactone-containing metabolites from a marine derived bacterium of the genusStreptomyces J Nat Prod2001 64664667

    Not in our library10.1021/np000599g

  175. 175.

    Mukku VJ Speitling M Laatsch H Helmke E New butenolides from two marine streptomycetesJ Nat Prod2000 6315701572

    Not in our library10.1021/np0001676

  176. 176.

    Tsujibo H Sato T Inui M Yamamoto H Inamori Y Intracellular accumulation of phenazine antibiotics produced by an alkalophilic actinomycete. I. Taxonomy, isolation and identification of the phenazine antibioticsAgric Biol Chem1988 52301306

    Not in our library

  177. 177.

    Breitmaier E Hollstein U Carbon-13 nuclear magnetic resonance chemical shifts of substituted phenazinesJ Org Chem1976 4121042108

    Not in our library

  178. 178.

    Hasegawa K Ueno Y The carbon-13 NMR spectra and electronic structure of 3H-phenoxazin-3-onesBull Chem Soc1985 5828322839

    Not in our library

  179. 179.

    Maskey RP Li F Qin S Fiebig HH Laatsch H Chandrananimycins A-C: production of novel anticancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of medium composition and growth conditionsJ Antibiot2003 56622629

    Not in our library10.7164/antibiotics.56.622

  180. 180.

    Cui CB Liu HB Gu JY Gu QQ Cai B Zhang DY Zhu TJ Echinosporins as new cell cycle inhibitors and apoptosis inducers from marine-derived Streptomyces albogriseolusFitoterapia2007 78238240

    Not in our library10.1016/j.fitote.2006.11.017

  181. 181.

    Sato T Kawamoto I Oka T Okachi R A new antibiotic echinosporin (XK-213)-producing organism, isolation and characterizationJ Antibiot1982 35266271

    Not in our library10.7164/antibiotics.35.266

  182. 182.

    Dübeler A Krastel P Floss HG Zeeck A Biosynthesis of the antibiotic echinosporin by a novel branch of the shikimate pathwayEur J Org Chem2002 6983987

    Not in our library

  183. 183.

    Morimoto M Imai R Antitumor activity of echinosporinJ Antibiot1985 38490495

    Not in our library10.7164/antibiotics.38.490

  184. 184.

    Lee HK Lee DS Lim J Kim JS Im KS Jung JH Topoisomerase I inhibitors from the Streptomyces sp. strain KM86-9B isolated from a marine spongeArch Pharm Res1998 21729733

    Not in our library10.1007/bf02976766

  185. 185.

    Kamal N Sabaratnam V Abdullah N Ho AS Teo SH Lee HB Light-activated cytotoxic compounds from Malaysian microorganisms for photodynamic therapy of cancerAntonie van Leeuwenhoek2009 95179188

    Not in our library10.1007/s10482-008-9301-8

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.